IN2014MN02657A - - Google Patents
Info
- Publication number
- IN2014MN02657A IN2014MN02657A IN2657MUN2014A IN2014MN02657A IN 2014MN02657 A IN2014MN02657 A IN 2014MN02657A IN 2657MUN2014 A IN2657MUN2014 A IN 2657MUN2014A IN 2014MN02657 A IN2014MN02657 A IN 2014MN02657A
- Authority
- IN
- India
- Prior art keywords
- compounds
- infections
- esters
- useful
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261657562P | 2012-06-08 | 2012-06-08 | |
PCT/US2013/044812 WO2013185093A1 (fr) | 2012-06-08 | 2013-06-07 | Inhibiteurs macrocycliques de virus flaviviridae |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN02657A true IN2014MN02657A (fr) | 2015-08-28 |
Family
ID=48626704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2657MUN2014 IN2014MN02657A (fr) | 2012-06-08 | 2013-06-07 |
Country Status (34)
Country | Link |
---|---|
US (4) | US9062092B2 (fr) |
EP (2) | EP3392253B1 (fr) |
JP (1) | JP6273268B2 (fr) |
KR (1) | KR102185152B1 (fr) |
CN (1) | CN104781261B (fr) |
AP (1) | AP2015008189A0 (fr) |
AR (1) | AR091279A1 (fr) |
AU (1) | AU2013270670B2 (fr) |
BR (1) | BR112014030639A2 (fr) |
CA (1) | CA2875690C (fr) |
CL (1) | CL2014003337A1 (fr) |
CR (1) | CR20150018A (fr) |
EA (1) | EA027134B1 (fr) |
EC (1) | ECSP15000435A (fr) |
ES (2) | ES2672480T3 (fr) |
HK (2) | HK1209731A1 (fr) |
IL (1) | IL236007B (fr) |
IN (1) | IN2014MN02657A (fr) |
MA (1) | MA37712B1 (fr) |
MD (1) | MD20140135A2 (fr) |
MX (1) | MX358372B (fr) |
NO (1) | NO2885641T3 (fr) |
NZ (1) | NZ703062A (fr) |
PE (1) | PE20150862A1 (fr) |
PH (1) | PH12014502739A1 (fr) |
PL (1) | PL2861601T3 (fr) |
PT (1) | PT2861601T (fr) |
SG (2) | SG11201408064PA (fr) |
SI (1) | SI2861601T1 (fr) |
TW (1) | TWI616448B (fr) |
UA (1) | UA115664C2 (fr) |
UY (1) | UY34851A (fr) |
WO (1) | WO2013185093A1 (fr) |
ZA (1) | ZA201409215B (fr) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
IN2014MN02658A (fr) | 2012-06-08 | 2015-08-21 | Gilead Sciences Inc | |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
ES2624223T3 (es) | 2012-06-08 | 2017-07-13 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de los virus flaviviridae |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
DK2950786T3 (da) | 2013-01-31 | 2020-02-17 | Gilead Pharmasset Llc | Kombinationsformulering af to antivirale forbindelser |
ES2792503T3 (es) | 2013-08-27 | 2020-11-11 | Gilead Pharmasset Llc | Formulación combinada de dos compuestos antivirales |
US20150150897A1 (en) | 2013-12-02 | 2015-06-04 | Gilead Pharmasset Llc | Methods of treating hepatitis c virus infection in subjects with cirrhosis |
TW201609785A (zh) | 2013-12-23 | 2016-03-16 | 吉李德製藥公司 | 固體型之抗病毒化合物 |
EP3092229B1 (fr) | 2014-01-06 | 2018-03-28 | Bristol-Myers Squibb Company | Dérivés de pyrrolidinyl sulfone et leur utilisation comme modulateurs de ror gamma |
ES2892123T3 (es) | 2014-12-26 | 2022-02-02 | Univ Emory | Derivados antivíricos de N4-hidroxicitidina |
EP3247378B8 (fr) | 2015-01-09 | 2023-08-23 | Revolution Medicines, Inc. | Composés macrocycliques participant à une liaison coopérative et leurs utilisations médicales |
CN107108615B (zh) | 2015-03-04 | 2020-11-20 | 吉利德科学公司 | Toll样受体调节性4,6-二氨基-吡啶并[3,2-D]嘧啶化合物 |
US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
EP3355930A4 (fr) | 2015-10-01 | 2019-03-06 | Warp Drive Bio, Inc. | Procédés et réactifs pour l'analyse d'interfaces protéine-protéine |
WO2017184670A2 (fr) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Méthodes de traitement d'infections à virus zika |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197055A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
WO2017197046A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
US11738013B2 (en) | 2016-05-27 | 2023-08-29 | Gilead Sciences, Inc. | Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors |
BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
EP3507276B1 (fr) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Composés modulateurs du recepteur de type toll |
DK3526323T3 (da) | 2016-10-14 | 2023-06-26 | Prec Biosciences Inc | Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet |
WO2018136559A1 (fr) * | 2017-01-17 | 2018-07-26 | The Regents Of The University Of California | Méthodes de traitement des flavivirus et des infections par le virus zika |
AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
EP3601267A1 (fr) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-méthyl-quinazolines |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
WO2018232174A2 (fr) * | 2017-06-16 | 2018-12-20 | Avalon Flaviviral Therapeutics (Hk) Limited | Compositions et procédé pour le traitement d'infections de flavivirus |
WO2019040102A1 (fr) | 2017-08-22 | 2019-02-28 | Gilead Sciences, Inc. | Composés hétérocycliques thérapeutiques |
GB2581936B (en) | 2017-12-07 | 2021-02-10 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
EP3728283B1 (fr) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
SG11202007646UA (en) | 2018-02-13 | 2020-09-29 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
EP3781565A1 (fr) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-méthyl-aza-quinazolines |
TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
KR102629921B1 (ko) | 2018-07-06 | 2024-01-31 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
CA3103987C (fr) | 2018-07-06 | 2023-08-01 | Gilead Sciences, Inc. | Composes heterocycliques therapeutiques |
TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
WO2020092528A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
JP7460644B2 (ja) | 2018-10-31 | 2024-04-02 | ギリアード サイエンシーズ, インコーポレイテッド | Hpk1阻害剤としての置換6-アザベンゾイミダゾール化合物 |
BR112021012057A2 (pt) * | 2018-12-21 | 2021-10-19 | Revolution Medicines, Inc. | Compostos que participam de ligação cooperativa e usos dos mesmos |
EP3934757B1 (fr) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
EP3935065A1 (fr) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
AU2020231115A1 (en) | 2019-03-07 | 2021-08-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
CA3140708A1 (fr) | 2019-06-18 | 2020-12-24 | Helen Horton | Association de vaccins contre le virus de l'hepatite b (vhb) et de derives de pyridopyrimidine |
EP3990476A1 (fr) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
WO2021011891A1 (fr) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Formulations à action prolongée de ténofovir alafénamide |
EP4017476A1 (fr) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
CA3149557A1 (fr) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Vaccins contre le virus de l'hepatite b et methodes de traitement du vhb |
CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
EP4054719A1 (fr) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
CN114867735A (zh) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | Ras抑制剂 |
CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
JPWO2021221043A1 (fr) * | 2020-04-30 | 2021-11-04 | ||
WO2022031894A1 (fr) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Promédicaments d'analogues nucléotidiques de phosphonamide et leur utilisation pharmaceutique |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
CA3222439A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes modulant les diacylglycerol kinases |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
WO2022271650A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
EP4359415A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
GB202207348D0 (en) | 2022-05-19 | 2022-07-06 | Cypralis Ltd | Macrocyclic compounds and uses thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62193147A (ja) | 1986-02-19 | 1987-08-25 | Toshiba Corp | 半導体装置の製造方法 |
US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
AR006514A1 (es) * | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
AU7743400A (en) | 1999-10-04 | 2001-05-10 | Merck & Co., Inc. | Integrin receptor antagonists |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
MX2007000040A (es) | 2004-06-30 | 2007-03-07 | Schering Corp | N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas. |
CA2612344A1 (fr) | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrogues d'antagonistes de recepteur d'adenosine a2b |
JP2008546708A (ja) * | 2005-06-17 | 2008-12-25 | ノバルティス アクチエンゲゼルシャフト | Hcvにおけるサングリフェリンの使用 |
CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
WO2009088256A2 (fr) | 2008-01-09 | 2009-07-16 | Konkuk University Industrial Cooperation Corp | Vaccins à base de baculovirus |
US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8927722B2 (en) * | 2008-12-23 | 2015-01-06 | Janssen Pharmaceutica N.V. | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV |
JP5868872B2 (ja) | 2010-01-15 | 2016-02-24 | ギリアード サイエンシーズ, インコーポレイテッド | フラビウイルス科ウイルスのインヒビター |
WO2011098808A1 (fr) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Composés à base de sangliféhrine |
GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
WO2012040040A1 (fr) | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Inhibiteurs de protéase ns3 du vhc |
UY33775A (es) | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
ES2624223T3 (es) | 2012-06-08 | 2017-07-13 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de los virus flaviviridae |
CA2873570C (fr) | 2012-06-08 | 2016-11-01 | Glenmark Pharmaceuticals S.A. | Amides de composes de 2-amino-4-arylthiazole et leurs sels comme modulateurs trpa1 |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
IN2014MN02658A (fr) | 2012-06-08 | 2015-08-21 | Gilead Sciences Inc |
-
2013
- 2013-06-05 AR ARP130101987 patent/AR091279A1/es unknown
- 2013-06-06 TW TW102120164A patent/TWI616448B/zh active
- 2013-06-06 UY UY0001034851A patent/UY34851A/es not_active Application Discontinuation
- 2013-06-07 SG SG11201408064PA patent/SG11201408064PA/en unknown
- 2013-06-07 EP EP18155377.7A patent/EP3392253B1/fr active Active
- 2013-06-07 PT PT137292405T patent/PT2861601T/pt unknown
- 2013-06-07 MD MDA20140135A patent/MD20140135A2/ro not_active Application Discontinuation
- 2013-06-07 IN IN2657MUN2014 patent/IN2014MN02657A/en unknown
- 2013-06-07 ES ES13729240.5T patent/ES2672480T3/es active Active
- 2013-06-07 NZ NZ703062A patent/NZ703062A/en not_active IP Right Cessation
- 2013-06-07 MA MA37712A patent/MA37712B1/fr unknown
- 2013-06-07 ES ES18155377T patent/ES2894269T3/es active Active
- 2013-06-07 WO PCT/US2013/044812 patent/WO2013185093A1/fr active Application Filing
- 2013-06-07 SI SI201331014T patent/SI2861601T1/en unknown
- 2013-06-07 AP AP2015008189A patent/AP2015008189A0/xx unknown
- 2013-06-07 US US13/913,288 patent/US9062092B2/en active Active
- 2013-06-07 SG SG10201703969PA patent/SG10201703969PA/en unknown
- 2013-06-07 PL PL13729240T patent/PL2861601T3/pl unknown
- 2013-06-07 CA CA2875690A patent/CA2875690C/fr active Active
- 2013-06-07 PE PE2014002395A patent/PE20150862A1/es not_active Application Discontinuation
- 2013-06-07 MX MX2014014765A patent/MX358372B/es active IP Right Grant
- 2013-06-07 AU AU2013270670A patent/AU2013270670B2/en active Active
- 2013-06-07 JP JP2015516258A patent/JP6273268B2/ja active Active
- 2013-06-07 BR BR112014030639A patent/BR112014030639A2/pt not_active Application Discontinuation
- 2013-06-07 EA EA201492188A patent/EA027134B1/ru not_active IP Right Cessation
- 2013-06-07 CN CN201380040628.8A patent/CN104781261B/zh active Active
- 2013-06-07 EP EP13729240.5A patent/EP2861601B1/fr active Active
- 2013-06-07 KR KR1020157000179A patent/KR102185152B1/ko active IP Right Grant
- 2013-07-06 UA UAA201413748A patent/UA115664C2/uk unknown
- 2013-08-16 NO NO13830006A patent/NO2885641T3/no unknown
-
2014
- 2014-11-30 IL IL236007A patent/IL236007B/en active IP Right Grant
- 2014-12-05 CL CL2014003337A patent/CL2014003337A1/es unknown
- 2014-12-05 PH PH12014502739A patent/PH12014502739A1/en unknown
- 2014-12-15 ZA ZA2014/09215A patent/ZA201409215B/en unknown
-
2015
- 2015-01-07 EC ECIEPI2015435A patent/ECSP15000435A/es unknown
- 2015-01-19 CR CR20150018A patent/CR20150018A/es unknown
- 2015-05-21 US US14/719,242 patent/US9642889B2/en active Active
- 2015-10-22 HK HK15110380.0A patent/HK1209731A1/xx unknown
-
2016
- 2016-01-13 HK HK16100361.3A patent/HK1212349A1/xx unknown
- 2016-04-08 US US15/094,777 patent/US20160220633A1/en not_active Abandoned
-
2017
- 2017-02-02 US US15/423,469 patent/US10472392B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN02657A (fr) | ||
IN2014MN02652A (fr) | ||
IN2014MN02658A (fr) | ||
PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
HK1166788A1 (fr) | ||
MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
MX2013006475A (es) | Inhibidores macrociclicos de virus flaviviridae. | |
IN2012DN01855A (fr) | ||
IN2015DN01156A (fr) | ||
WO2014028600A3 (fr) | Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci | |
IN2015DN01119A (fr) | ||
MX2015013224A (es) | Inhibidores macrociclicos y biciclicos del virus de la hepatitis c. | |
IN2011CH03893A (fr) |